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Recently, five glycopeptides with coronaro-constrictory properties were isolated from bovine hypothalamus [(1988) Neurochemistry (USSR) 7,519- 
5241. Calmodulin has been recognized in our laboratory as a target protein for the neuropeptides isolated from hypothalamus. The results of indirect 
enzyme-linked immunosorbent assay have shown that the new hypothalamic neuropeptides antagonize with the monospecific anti-calmodulin anti- 
body for calmodulin binding although they are not fragments of calmodulin. The inhibitory potency of the peptides is dependent on their concentra- 
tion and the length of the polypeptide chain. Four out of five peptides are effective in nM concentration range. Ca*+ stimulates the binding of 
peptides to calmodulin; however, immunocomplex can be formed in the absence of Ca*+ as well. The effects of trifluoperazine and peptides on 
the calmodulin/antibody interaction are not additive, suggesting the cooperativity between the binding sites on calmodulin. Under physiological 
conditions the presence of the peptides could produce distinct conformers of calmodulin which may exhibit altered potency for stimulation/in- 
hibition of target enzymes. 
Anti-CaM activity; Neuropeptide; Enzyme-linked immunosorbent assay; Cooperative binding 
1. INTRODUCTION 
Galoyan and his coworkers [I] isolated five 
neuropeptides with molecular masses of 3, 3.5, 3.5, 3.5 
and 7 kDa from bovine hypothalamus. Determination 
of amino acid compositions have shown their high Ser, 
Gly and Glu content. Both acidic and enzymatic 
hydrolyses resulted in the loss of activity of these pep- 
tides [2]. Recently, it has been shown that two of these 
peptides stimulate the calmodulin-sensitive activities of 
PDE and that all stimulate the MLCK activity in the 
absence of Ca2 + [2,3]. This finding may indicate that 
the effective peptides could perform the function of en- 
dogenous substitutes of Ca2 + [4]. 
CaM is involved in the regulation of numerous 
Ca2 + -mediated events [5,6] and it can mediate activa- 
tion/inhibition of target enzymes; however, the precise 
mechanism of its action regulating metabolic processes 
has not been defined ([7] and references therein). Anti- 
CaM drugs prevent or modify the interactions of CaM 
with target enzymes. The binding sites for a classic CaM 
antagonist, TFP, in the N- and C-terminal domains of 
CaM are identified [8]. The C-terminal domain of CaM 
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has been shown to be the important region for im- 
munoreactivity [9]. 
In this work we have investigated the anti-CaM ac- 
tivity of the coronaro-constrictory peptides using a sen- 
sitive immunochemical approach which requires small 
quantity of the hypothalamic neuropeptides. This ap- 
proach renders it possible to detect the binding of pep- 
tides to CaM, to analyse the mutual effect of the 
neuropeptides and TFP on the immunocomplex forma- 
tion and to study the Ca2+-sensitivity of the binding. 
2. MATERALS AND METHODS 
CaM from human erythrocytes was purified to homogeneity using 
trifluoperazine-Sepharose-4B chromatography [lo]. Rabbits were im- 
munized with I-fluoro-2,4-dinitrobenzene derivatized bovine CaM as 
described in [ll]. The IgG fraction was isolated from the antiserum 
using the QAE-Sephadex A-50 (Pharmacia) chromatographic method 
[12]. Monospecific antibodies were further purified on a CaM- 
Sepharose-4B affinity column [14,15]. 
Standard ELISA protocols [14] for indirect assays were used with 
some modifications as follows. Indirect assay: coating of plate with 
human CaM was done for 18 h at 6°C. Antibodies were diluted in 
wells, and the plate was allowed to stand for 2 h at room temperature. 
The goat anti-rabbit globulin conjugated with horseradish peroxidase 
(Human, Budapest, Hungary) at 1000 times dilution was allowed to 
interact for 2 h at room temperature. o-Phenylenediamine, with 
peroxide added, was used as substrate solution. Plates were read at 
492 nm after 1 h of substrate hydrolyzis time. The OD 49znm values are 
the average of least five measurements. Error of determination is * 
10%. 
Peptides were isolated from bovine hypothalamus by gel-filtration 
on Sephadex G-10, ion-exchange chromatography on Dowex 
50W x 8, and high-performance liquid chromatography on Nucleosil 
Cis semipreparative reverse-phase column (0.46~ 25 cm) [l]. 
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Fig. 1. Displacement curves of peptides and TFP at 2.5 pg/ml coating 
concentrations of CaM and 7.5 fig/ml antibody concentration. For 
other details see section 2. (x) Pi; (0) Pz; (0) PJ; (A.) P4; (+) Ps; (I) 
TFP. 
3. RESULTS AND DISCUSSION 
3. I. The binding of peptides and TFP to CaM 
Enzyme-linked immunoassay has been found to be 
especially sensitive for the detection of binding of en- 
zymes or ligands like drugs to CaM [7]. We have 
demonstrated previously [ 131 that the sera did not form 
precipitine lines in double diffusion with CaM, and 
‘sandwich’ ELISA [ 141 was nonreactive when anti-CaM 
IgG was applied. These observations, in accordance 
with the literary data, suggest hat only major antigenic 
site is present on the CaM molecules [l 1 J. 
Table I 
Effect of neuropeptides and CaM on antibody/anti-antibody interac- 
tions 
Additions [Abtmmobitized] Dilution ODwanm 
&W &9W of anti-antibody 
no 5 1:2000 
no 5 1:lOOO 
IlO 5 1:500 
no 10 I:1000 0.130 
no 10 I:500 0.230 
CaM (0.15) 10 1:500 0.165 
Pz (0.207) 10 1:500 0.230 
Pz (0.006) 10 1:500 0.230 
Pq (0.207) 10 1:500 0.230 
P4 (0.006) 10 I:500 0.220 
For details see section 2. 
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We have used indirect ELISA to investigate whether 
coronaro-constrictory peptides can display anti-CaM 
activity. On the basis of the optimization experiments, 
2.5 pglml CaM and 7.5 fig/ml antibody were found to 
ensure the very sensitive detection of relationships of 
antigen/antibody [13]. Fig. 1 shows the effect of 
neuropeptides (PI-P5) on the immunocomplex forma- 
tion in a range of peptide concentrations. The dilution 
curve of a ‘classic’ CaM antagonist, TFP, was also 
measured under the same conditions. Binding of an- 
tibody to CaM was agressively inhibited by increasing 
the concentrations of PI-P4; however, PS exhibited 
much less effect. The concentrations inducing 50% in- 
hibition (Ire) of the formation of immunocomplex are 
2.5, 4.6, 15.8 and 31.6 nM, for Pi, Pz, P3 and P4, 
respectively. Therefore, it can be concluded that (i) 
PI-P4 are much more potent inhibitors of the im- 
munocomplex formation than TFP; (ii) while the pep- 
tides exhibit simple displacement curves, the effect of 
TFP on the binding of antibody to CaM seems to be 
more complex 171. The anti-CaM activity of the pep- 
tides can be interpreted in two different ways: (i) the 
peptides form a complex with CaM and inhibit the for- 
mation of immunocomplex; (ii) the peptides as real or 
apparent fragments of CaM bind directly to antibody 
and the binding sites are not accessible to the intact 
CaM. To distinguish between these two possibilities, 
the binding of peptides to antibody has been tested. To 
solid-phase immobilized antibody, anti-antibody was 
added at subsaturating concentrations in the absence 
and the presence of peptides (Table I). The presence of 
peptides did not perturb anything; however, CaM im- 
pedes the binding of anti-antibody to antibody. This 
observation together with the data presented in Fig. 1 
suggests that the peptides are not the fragments of 
CaM. This idea is also supported by the comparison of 
amino acid compositions of peptides and segments of 
CaM [I]. 
It can be seen from the results that the inhibitory 
potency of the peptides decreased with increasing length 
of the polypeptide chain. Ps, having about the double 
molecular mass (Mw 7000) compared to the other four 
peptides, has much less effect on antibody binding to 
CaM. Although the sequences of the neuropeptides 
have not been determined, their amino acid composi- 
tions suggest hat the smaller peptides cannot be deduc- 
ed from the larger. 
To investigate whether the binding of peptides to 
CaM interferes with that of TFP, they were added 
together to the ELISA mixture. At constant concentra- 
tions of the peptides which induce 50% inhibition of the 
formation of CaM-antibody complex, the concentra- 
tions of TFP were varied (Ps was used in higher concen- 
tration: 100 nM). As shown in Fig. 3, while PS had prac- 
tically no effect on the TFP dilution curve (cf. Fig. I), 
the other peptides could eliminate partially or complete- 
ly the activating effect of TFP on the antibody binding 
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Fig. 2. Mutual effects of TFP and peptides on the binding of antibody 
to CaM. The concentrations of CaM and antibody were 2.5 ,ug/ml 
and 7.5 pg/ml, respectively. (A) The concentration of peptides was 
kept constant: 2.5, 4.6, 15.8 and 31.6 nM for PI (x), PZ (0), P4 (A) 
and Ps (+), respectively. For other details see the text. 
to CaM. As a simple interpretation of these ex- 
periments, only one binding site for the peptides has 
been assumed. It is known from the literature that both 
N- and C-terminal domains of CaM have one TFP bin- 
ding site each [15], and the monospecific-antibody in- 
teracts with the antigenic site in C-terminal domain 
[16]. While the binding of TFP to the N-terminal do- 
main may stimulate the binding of antibody to CaM, 
the binding of TFP to the C-terminal domain may com- 
pete with antibody for CaM binding [7]. The binding of 
the peptides to CaM prevents the immunocomplex for- 
mation. Since the effect of the peptides on the antibody 
binding to CaM is more pronounced in the presence of 
low concentrations of TFP than in its absence or in the 
presence of high concentrations of TFP, it can be 
hypothesized that the peptides and TFP at low concen- 
trations can bind simultaneously to CaM, and within 
this ternary complex CaM loses the ability to interact 
with antibody. Therefore, it seems likely that the bin- 
ding sites for peptides and TFP are different and in- 
teract in a cooperative manner on the surface of CaM. 
3.2. Effect of Ca2 ’ on the binding of peptides to CaM 
In order to investigate the role of Ca2+ in the interac- 
tion between CaM and neuropeptides, we analysed the 
formation of the immunocomplex in the presence of 
peptides under various conditions. Control experiments 
showed that the formation of CaM-antibody complex is 
Ca2 + -dependent; however, the presence of Ca2 + was 
important merely during but not after the coating pro- 
cedure (data not shown). This finding can be inter- 
preted to mean that CaM molecules could, at least part- 
ly, preserve their active conformations induced by 
Ca2 + in solid-phase bound form. 
We have carried out two sets of experiments with 
neuropeptides. A representative xperiment carried out 
with P2 is presented in Fig. 3. In one set Ca2+ -CaM 
complex was coated to the plate and the assay was fur- 
ther done in the presence of 1 mM CaC12 or 1 mM 
EGTA. The binding of antibody to CaM was inhibited 
by peptide; however, the degree of inhibition does not 
depend on the presence of Ca2+ in solution. In the sec- 
ond set of experiments, CaM was coated to the plate in 
the absence of Ca2 + , then the mixture of the peptide 
and antibody was added to the solid-phase bound CaM 
in the presence of 1 mM Ca2+ or 1 mM EGTA. As 
shown in Fig. 3, the inhibitory effect of peptides 
manifests itself at higher peptide concentrations if the 
assay did not contain Ca2 + at all. Since the inhibition 
percentages are referred to the corresponding control 
measured in the absence of peptide; thus, it can be con- 
cluded that although neuropeptides can bind to Ca-free 
CaM, the peptides display higher affinity toward 
Ca2 + -CaM complex. Investigations with other peptides 
showed similar results (data not shown). 




Fig. 3. Effect of Ca’+ on the binding of P2 to CaM. The concentra- 
tions of CaM and antibody were 2.5 pg/ml and 7.5 @g/ml, respective- 
ly. CaM was coated to the microplate in the presence of 1 mM Ca2+, 
and the assay contained 1 mM Ca2+ (0) or 1 mM EGTA (0). CaM 
was coated to the microplate in the absence of 1 mM Ca2+, and the 
assay contained 1 mM Ca2+ (A) or 1 mM EGTA (A). For other 
details see section 2. 
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to CaM in a Ca’ + -dependent manner [6,7] and that this 
bin,ding can be enhanced by interaction of CaM an- 
tagonists at distinct sites via an allosteric mechanism. 
Newton [ 171 has observed increased rates of incorpora- 
tion of affinity label when TFP was added at low con- 
centration. We have previously shown that CaM can in- 
teract simultaneously with target enzyme and fendiline 
[ 181. In this study evidence is presented that the 
neuropeptides inhibit not only the binding of antibody 
to CaM, but also eliminate the activating effect of TFP. 
Therefore, a combined binding of peptides and TFP to 
CaM has been assumed which induces the formation of 
a distinct ternary structure for CaM. In addition, it can 
be hypothesized that the concentrations of both 
neuropeptides and Ca2 + could be responsible for the 
regulation of the ratio of the active and inactive con- 
formers of CaM. Thus, the neuropeptides from the 
hypothalamus as ellosteric regulators of CaM could 
alter its sensitivity to drugs and influence selectivity for 
CaM binding to its target proteins. 
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